Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Lung Cancer
•
Thoracic Malignancies
•
Medical Oncology
•
Small cell lung cancer
Can Dupixent and Durvalumab be used at the same time in a patient with extensive stage small cell lung cancer?
Would they significantly interfere with each other? Thank you.
Related Questions
What are your top takeaways in Thoracic Cancers from ASCO 2025?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
What are the main practical factors to consider when using bispecific antibody therapy (Tarlatamab) for extensive-stage small cell lung cancer?
In ES-SCLC presenting with extensive brain metastases, how do you time whole brain radiation after the first cycle of chemotherapy has already been delivered?
When will you choose Tarlatamab over an alternative systemic therapy (e.g. lurbinectedin, topotecan) for relapsed ES SCLC?
How would you approach treatment for patients with limited stage small cell lung cancer (SCLC) who, after induction chemotherapy with carboplatin/etoposide, develop a new contralateral lung nodule confirmed as SCLC, while their primary tumor shows a partial response?
Would you consider delaying tarlatamab initiation in a patient with ES SCLC who recently completed RT for CNS disease, given the concern for immune effector cell-associated neurotoxicity syndrome (ICANS)?
How do you approach Tarlatamab use in an elderly patient with relapsed ES SCLC?
Is DLL3 expression necessary for tarlatamab efficacy in small cell lung cancer?
Would you change systemic therapy in a patient with SCLC with stable systemic disease but CNS progression?